Astellas Pharma Inc.
ALPMFOTCHealthcare● Active
$14.48
+$0.28(+1.99%)
Market Cap$25.9B
P/E Ratio—
52W High$17.85
52W Low$9.34
Astellas Pharma Inc. (ALPMF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALPMF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.293T | $0.031T | $0.017T | $0.132T | $0.157T |
| Depreciation & Amort. | $0.196T | $0.199T | $0.158T | $0.106T | $0.080T |
| Stock-Based Comp. | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Change in Working Capital | $0.028T | ($0.166T) | ($0.087T) | ($0.024T) | $0.006T |
| Net Cash from Operations | $0.570T | $0.195T | $0.172T | $0.328T | $0.257T |
| Investing Activities | |||||
| Capital Expenditure | ($0.058T) | ($0.057T) | ($0.082T) | ($0.089T) | ($0.076T) |
| Purchases of Investments | $0.000T | $0.000T | $0.000T | $0.000T | ($0.006T) |
| Sales of Investments | $0.000T | $0.013T | $0.000T | $0.013T | $0.006T |
| Net Cash from Investing | ($0.073T) | ($0.089T) | ($0.846T) | ($0.085T) | ($0.062T) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.001T) | ($0.007T) | ($0.011T) | ($0.061T) | ($0.051T) |
| Dividends Paid | ($0.137T) | ($0.129T) | ($0.117T) | ($0.100T) | ($0.085T) |
| Debt Issued / Repaid | ($0.269T) | ($0.089T) | $0.771T | ($0.015T) | ($0.060T) |
| Net Cash from Financing | ($0.407T) | ($0.261T) | $0.614T | ($0.196T) | ($0.216T) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.512T | $0.137T | $0.090T | $0.239T | $0.181T |
| FCF Margin %(computed) | 23.77% | 7.17% | 5.61% | 15.75% | 13.96% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · JPY · T
Explore more Astellas Pharma Inc. data
About Astellas Pharma Inc. (ALPMF) Cash Flow Statement
Astellas Pharma Inc. generated operating cash flow of $569.82B and free cash flow of $511.73B for 2026 — a FCF margin of 23.77%. Capital expenditure was ($58.09B).
Frequently asked questions
ALPMF · 4 questionsAstellas Pharma Inc. generated free cash flow of $511.73B for 2026, up 273.0% year-over-year.
ALPMF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10